|
|||||
|
|
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma |
|
| Authors: | Michael Dickinson David Ritchie Daniel J. DeAngelo rew Spencer Oliver G. Ottmann Thomas Fischer Kapil N. Bhalla Angela Liu Katie Parker Jeffrey W. Scott Mark Bishton H. Miles Prince |
| Affiliation: | Haematology Service, Peter MacCallum Cancer Centre and;University of Melbourne, Melbourne, Vic., Australia;, Adult Oncology, Dana–Farber Cancer Institute, Boston, MA, USA;, Clinical Haematology &BMT, Alfred Hospital, Melbourne, Vic., Australia;, Medizinische Klinik II, University of Frankfurt, Frankfurt, Germany;, Department of Hematology and Oncology, Otto- von Guericke University, Magdeburg, Germany;, Medical College of Georgia Cancer Center, Augusta, GA;, and Novartis Oncology, Florham Park, NJ, USA |
| Abstract: | There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by |
| Keywords: | Hodgkin lymphoma HDAC inhibitor LBH589 panobinostat |